Format

Send to

Choose Destination
Nature. 2018 Jun;558(7710):E1. doi: 10.1038/s41586-018-0111-5.

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.

Author information

1
Discovery, Global Pharmaceutical Research and Development, North Chicago, IL, USA.
2
eFFECTOR Therapeutics, San Diego, CA, USA.
3
Petra Pharma Corporation, New York, NY, USA.
4
Faraday Pharmaceuticals, Seattle, WA, USA.
5
Department of Proteomics, the Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
6
Cascadian Therapeutics, Inc., Seattle, WA, USA.
7
I-to-D, Inc., Lincoln, MA, USA.
8
Mitobridge, Inc., Cambridge, MA, USA.
9
Van Drie Research, Andover, MA, USA.
10
China Novartis Institutes for BioMedical Research, Zhangjiang Hi-Tech Park, Shanghai, China.
11
Accelerator Corporation, New York, NY, USA.
12
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
13
Johns Hopkins University, Baltimore, MA, USA.
14
Discovery, Global Pharmaceutical Research and Development, North Chicago, IL, USA. Kenneth.Bromberg@abbvie.com.

Abstract

In the originally published version of this Letter, the authors Arthur F. Kluge, Michael A. Patane and Ce Wang were inadvertently omitted from the author list. Their affiliations are: I-to-D, Inc., PO Box 6177, Lincoln, Massachusetts 01773, USA (A.F.K.); Mitobridge, Inc. 1030 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA (M.A.P.); and China Novartis Institutes for BioMedical Research, No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong District, Shanghai 201203, China (C.W.). These authors contributed to the interpretation of results and design of compounds. In addition, author 'Edward A. Kesicki' was misspelled as 'Ed Kesicki'. These errors have been corrected online.

PMID:
29769713
DOI:
10.1038/s41586-018-0111-5

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center